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Background
HD IL-2 was FDA approved for advanced melanoma,
but the data supporting its use dates to the 1990’s. The
PROCLAIMSM registry (http://www.proclaimregistry.
com) is the largest collection of IL-2 treated patients in
the US and provides real-time insights into patient sur-
vival and outcomes. Previously, we reported a median
overall survival (mOS) of 20 months with a median fol-
low-up of 37 months in metastatic melanoma (mM)
patients treated with high dose IL-2 (HD IL-2) between
2007 and 2012 from a retrospective cohort. These find-
ings led to the hypothesis that improved mOS may have
been a result of subsequent salvage therapies, including
checkpoint inhibitors.
Methods
Patients must have received at least one dose of HD IL-
2 for this analysis. Those that received checkpoint ther-
apy prior to HD IL-2 were excluded. Statistics and sur-
vival analysis on prospectively entered patients (N=236)
were performed on datasets as of March 16th, 2015.
Results
The median overall survival (mOS) for the 236 patients
was 18.4 months with a median follow-up of 21.7
months. Patients were stratified into three groups;
HD IL-2 only (n=123), HD IL-2 followed by ipilimumab
(IL-2®ipi, n=78), and HD IL-2 followed by PD-1 inhibi-
tors (IL-2®aPD-1, n=35). The majority of patients (22
of 35) in the IL-2®aPD-1 group had progressive disease
before receiving subsequent treatment with anti-PD-1/
PD-L1-containing regimens. Patients in the HD IL-2
only, IL-2®ipi, and IL-2®aPD-1 groups achieved a
mOS of 14, 15.8, and 28.7 months, respectively. The
estimated 12-month survival rates were 57%, 64%, and
97%, respectively. There were 10/78 (13%) and 2/35
(5.7%) post therapy treatment-related incidences of
autoimmune events in the IL-2®ipi and IL-2®aPD-1
groups, respectively. No treatment related deaths were
reported.
Conclusions
This is the first report of clinical data relating to HD IL-
2 use followed by checkpoint blockade of the PD-1
pathway. Treatment with anti-PD-1 after initial therapy
with HD IL-2 had significantly prolonged survival com-
pared to patients treated with ipilimumab. Moreover,
improved survival was not observed in patients treated
with follow-on ipilimumab compared to patients treated
only with HD IL-2. Anti-PD-1 therapy after HD IL-2,
appears to be safe and therapeutically active. These data
support the concept of investigating IL-2 therapy in
combination or sequence with newly developed immune
checkpoint inhibitors.
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